Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor’s Brovana COPD Therapy Approved; Launch Planned For 2007

Executive Summary

Sepracor's newly approved long-acting beta2-agonist for chronic obstructive pulmonary disease appears to have a slower onset of effect than Novartis/Schering-Plough's Foradil

You may also be interested in...



No Breathing Room For Advair: GSK Combo Part Of Asthma Drug Restrictions

GlaxoSmithKline's asthma combination product Advair is included in an FDA advisory against first-line use of long-acting beta agonist bronchodilators despite an advisory committee review that suggested Advair was less risky than other products

Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval

Novartis will conduct holter heart monitoring in Foradil Aerolizer patients as a Phase IV commitment following the approval of formoterol for chronic obstructive pulmonary disease Sept. 25.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel